RU2413529C2 - Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа - Google Patents
Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа Download PDFInfo
- Publication number
- RU2413529C2 RU2413529C2 RU2008100307/15A RU2008100307A RU2413529C2 RU 2413529 C2 RU2413529 C2 RU 2413529C2 RU 2008100307/15 A RU2008100307/15 A RU 2008100307/15A RU 2008100307 A RU2008100307 A RU 2008100307A RU 2413529 C2 RU2413529 C2 RU 2413529C2
- Authority
- RU
- Russia
- Prior art keywords
- ifn
- cytokine
- family
- pegylated
- combinations
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 119
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 119
- 108090001005 Interleukin-6 Proteins 0.000 title claims abstract description 100
- 108010047761 Interferon-alpha Proteins 0.000 title claims description 138
- 102000006992 Interferon-alpha Human genes 0.000 title claims description 138
- 102000004889 Interleukin-6 Human genes 0.000 title description 72
- 239000000203 mixture Substances 0.000 title description 7
- 229940100601 interleukin-6 Drugs 0.000 title description 2
- 108010041776 cardiotrophin 1 Proteins 0.000 claims abstract description 86
- 108090000630 Oncostatin M Proteins 0.000 claims abstract description 54
- 102000004140 Oncostatin M Human genes 0.000 claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000003612 virological effect Effects 0.000 claims abstract description 22
- 102000014150 Interferons Human genes 0.000 claims abstract description 19
- 108010050904 Interferons Proteins 0.000 claims abstract description 19
- 229940079322 interferon Drugs 0.000 claims abstract description 19
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 134
- 102100028892 Cardiotrophin-1 Human genes 0.000 claims description 84
- 101710127457 Interferon alpha-5 Proteins 0.000 claims description 36
- 102100039948 Interferon alpha-5 Human genes 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 208000005176 Hepatitis C Diseases 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 abstract description 38
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 abstract description 38
- 108010044012 STAT1 Transcription Factor Proteins 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 230000006698 induction Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000029812 viral genome replication Effects 0.000 abstract description 4
- 108030002617 2'-5' oligoadenylate synthases Proteins 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 2
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 67
- 108010078049 Interferon alpha-2 Proteins 0.000 description 66
- 102100040018 Interferon alpha-2 Human genes 0.000 description 66
- 102000006381 STAT1 Transcription Factor Human genes 0.000 description 34
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 33
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 33
- 230000000840 anti-viral effect Effects 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 230000004913 activation Effects 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 230000010076 replication Effects 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 108010085238 Actins Proteins 0.000 description 11
- 208000036142 Viral infection Diseases 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 6
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 description 6
- 108010002871 cardiotrophin-like cytokine Proteins 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 5
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 208000002672 hepatitis B Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 4
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 4
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001120 cytoprotective effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 3
- 102100034343 Integrase Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- -1 STAT2 Proteins 0.000 description 3
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 3
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 208000000907 Condylomata Acuminata Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 101000992159 Homo sapiens Oncomodulin-1 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000014746 Interferon-Stimulated Gene Factor 3 Human genes 0.000 description 2
- 108010064052 Interferon-Stimulated Gene Factor 3 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 102100031945 Oncomodulin-1 Human genes 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 2
- 201000004201 anogenital venereal wart Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 208000018663 Central Nervous System Viral disease Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 101150009057 JAK2 gene Proteins 0.000 description 1
- 108010000837 Janus Kinase 1 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010040628 Sialoadenitis Diseases 0.000 description 1
- 101710140204 Signal transducer and transcription activator Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 101710085459 p48 protein Proteins 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940002988 pegasys Drugs 0.000 description 1
- 108010092853 peginterferon alfa-2a Proteins 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000009265 virologic response Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2073—IL-11
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5415—Leukaemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200501468 | 2005-06-16 | ||
| ES200501468A ES2302402B1 (es) | 2005-06-16 | 2005-06-16 | Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008100307A RU2008100307A (ru) | 2009-07-27 |
| RU2413529C2 true RU2413529C2 (ru) | 2011-03-10 |
Family
ID=37532659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008100307/15A RU2413529C2 (ru) | 2005-06-16 | 2006-06-16 | Применение цитокина из семейства интерлейкина-6 для получения композиции для комбинированного введения с интерфероном-альфа |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7829077B2 (enExample) |
| EP (1) | EP1905447A4 (enExample) |
| JP (1) | JP5154412B2 (enExample) |
| CN (1) | CN101257918B (enExample) |
| AU (1) | AU2006258966B8 (enExample) |
| BR (1) | BRPI0611988A2 (enExample) |
| CA (1) | CA2612282C (enExample) |
| ES (1) | ES2302402B1 (enExample) |
| MX (1) | MX2007016060A (enExample) |
| RU (1) | RU2413529C2 (enExample) |
| WO (1) | WO2006134195A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA106591C2 (uk) * | 2008-07-23 | 2014-09-25 | Тамара Алєксандровна Віткалова | Спосіб лікування гепатиту с з використанням інтерферону та інтерлейкіну-1 |
| JP2010059081A (ja) * | 2008-09-02 | 2010-03-18 | Okayama Univ | オンコスタチンｍを含有する抗ｈｃｖ剤およびその利用 |
| ES2342529B1 (es) | 2008-10-07 | 2011-05-11 | Proyecto De Biomedicina Cima, S.L. | Oncostatina m como potenciador de la actividad inmunoestimuladora de celulas epiteliales humanas. |
| WO2011098644A2 (es) | 2010-02-09 | 2011-08-18 | Proyecto De Biomedicina Cima, S.L. | Composiciones para el tratamiento de enfermedades infecciosas y tumorales |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN110636854A (zh) | 2017-03-31 | 2019-12-31 | 阿卡尼斯生物技术F&E有限责任两合公司 | 非黑素瘤皮肤癌(nmsc)的预防和治疗 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN113197910B (zh) * | 2021-05-14 | 2022-09-23 | 苏州大学 | 一种基于阿司匹林及其代谢产物提高干扰素抗病毒活性的抗病毒药盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0858343A1 (en) * | 1995-11-02 | 1998-08-19 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| RU2128056C1 (ru) * | 1992-04-15 | 1999-03-27 | Амген Инк. | Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6284237B1 (en) | 1986-07-08 | 2001-09-04 | Steven C. Clark | Methods of treatment using IL-6 |
| US6348191B1 (en) | 1986-07-08 | 2002-02-19 | Genetics Institute, Inc. | Production and use of IL-6 |
| IE67035B1 (en) * | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
| WO1998012332A1 (en) * | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions and methods for treating intracellular diseases |
| AR013269A1 (es) * | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| US6685931B1 (en) | 1998-12-22 | 2004-02-03 | Schering Corporation | Treatment of hepatitis C virus infections with interleukin-10 |
| ES2200646B1 (es) * | 2001-09-21 | 2005-05-01 | Fundacion Para La Investigacion Medica Aplicada | Uso de la cardiotrofina en enfermedades hepaticas. |
| TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
| US20050027110A1 (en) * | 2003-07-24 | 2005-02-03 | Michael Russell | Drug delivery in the nervous system |
-
2005
- 2005-06-16 ES ES200501468A patent/ES2302402B1/es not_active Expired - Fee Related
-
2006
- 2006-06-16 RU RU2008100307/15A patent/RU2413529C2/ru not_active IP Right Cessation
- 2006-06-16 JP JP2008516350A patent/JP5154412B2/ja not_active Expired - Fee Related
- 2006-06-16 BR BRPI0611988-3A patent/BRPI0611988A2/pt not_active IP Right Cessation
- 2006-06-16 AU AU2006258966A patent/AU2006258966B8/en not_active Ceased
- 2006-06-16 CA CA2612282A patent/CA2612282C/en not_active Expired - Fee Related
- 2006-06-16 CN CN2006800299002A patent/CN101257918B/zh not_active Expired - Fee Related
- 2006-06-16 US US11/922,221 patent/US7829077B2/en not_active Expired - Fee Related
- 2006-06-16 MX MX2007016060A patent/MX2007016060A/es active IP Right Grant
- 2006-06-16 WO PCT/ES2006/000353 patent/WO2006134195A2/es not_active Ceased
- 2006-06-16 EP EP06794028A patent/EP1905447A4/en not_active Withdrawn
-
2010
- 2010-09-22 US US12/887,843 patent/US20110027224A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2128056C1 (ru) * | 1992-04-15 | 1999-03-27 | Амген Инк. | Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами |
| EP0858343A1 (en) * | 1995-11-02 | 1998-08-19 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| RU2222345C2 (ru) * | 2002-01-21 | 2004-01-27 | Волчек Игорь Анатольевич | Фармацевтическая композиция цитокинового и иммуномодулирующего действия |
Non-Patent Citations (2)
| Title |
|---|
| Patterson ВК, Tjernlund A, Andersson J. «Endogenous inhibitors of HIV: potent anti-HIV activity of leukemia inhibitory factor.», Curr Mol Med. 2002 Dec; 2(8):713-22. * |
| Цитокины и воспаление, том 1, №1, 2002, А.С.Симбирцев, стр.10, 16. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006134195A8 (es) | 2008-01-31 |
| AU2006258966B8 (en) | 2011-12-08 |
| JP5154412B2 (ja) | 2013-02-27 |
| ES2302402B1 (es) | 2009-05-08 |
| US7829077B2 (en) | 2010-11-09 |
| WO2006134195A2 (es) | 2006-12-21 |
| EP1905447A2 (en) | 2008-04-02 |
| ES2302402A1 (es) | 2008-07-01 |
| CA2612282A1 (en) | 2006-12-21 |
| US20110027224A1 (en) | 2011-02-03 |
| CN101257918A (zh) | 2008-09-03 |
| AU2006258966B2 (en) | 2011-11-17 |
| CA2612282C (en) | 2014-03-25 |
| EP1905447A4 (en) | 2012-04-25 |
| CN101257918B (zh) | 2011-09-21 |
| BRPI0611988A2 (pt) | 2010-10-13 |
| WO2006134195A3 (es) | 2007-04-19 |
| RU2008100307A (ru) | 2009-07-27 |
| US20090130055A1 (en) | 2009-05-21 |
| AU2006258966A1 (en) | 2006-12-21 |
| MX2007016060A (es) | 2008-03-10 |
| JP2008546672A (ja) | 2008-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110027224A1 (en) | Use of a cytokine from the interleukin-6 family in the preparation of a composition for combined administration with interferon-alpha | |
| Pfitzner et al. | The role of STATs in inflammation and inflammatory diseases | |
| De Maeyer et al. | Type I interferons | |
| EP0741577B1 (en) | The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver | |
| Fox et al. | Context is key: delineating the unique functions of IFNα and IFNβ in disease | |
| Zhu et al. | Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication | |
| Lai et al. | Interferon therapy and its association with depressive disorders–A review | |
| Nair et al. | Interferon regulatory factor-1 protects from fatal neurotropic infection with vesicular stomatitis virus by specific inhibition of viral replication in neurons | |
| George et al. | Interferon-α subtypes as an adjunct therapeutic approach for human immunodeficiency virus functional cure | |
| Sutter et al. | Interferon α subtypes in HIV infection | |
| Radaeva et al. | Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C | |
| Nunnari et al. | IL-7 as a potential therapy for HIV-1-infected individuals | |
| US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
| Su et al. | New sights of low dose IL‐2: Restoration of immune homeostasis for viral infection | |
| KR101928564B1 (ko) | 인터페론 및 dna 메틸화 억제제를 유효성분으로 포함하는, b형 간염 바이러스 감염증 예방 및 치료용 약학적 조성물 | |
| WO2005016226A2 (en) | Pharmaceutical compositions comprising ccr5 antagonists | |
| JPWO2008004653A1 (ja) | ウイルス性疾患の予防又は治療剤 | |
| Novak et al. | Aberrant Activation of JAK/STAT Pathway Components in Response to G-CSF, Interferon-a/p and Interferon-y in NFS-60 Cells | |
| Larrea et al. | IFN-α 5 Mediates Stronger Tyk2-Stat-Dependent Activation and Higher Expression of 2′, 5′-Oligoadenylate Synthetase Than IFN-α 2 in Liver Cells | |
| Ishida et al. | Differential effects of a novel IFN-ζ/limitin and IFN-α on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes | |
| US20080069800A1 (en) | System for High Production of Natural and Personalized Interferons | |
| CN114404572A (zh) | 一种抗SARS-CoV2病毒感染导致的细胞因子风暴的药物 | |
| Civeira et al. | IFN-alpha5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2', 5'-oligoadenylate synthetase than IFN-alpha2 in liver cells | |
| Cook | Host Determinants of Protection and Pathogenesis during Chikungunya Virus Infection | |
| Li | TMEM203 is a putative co-receptor of innate immune adaptor protein STING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150617 |